Dexcom Faces US FDA Warning Amid Agency Review Of 15-Day Sensor
Warning Letter Is Temporary Setback But Unlikely To Result In Significant Market Share Loss, Analysts Say
Even if manufacturing challenges don’t derail the 2025 launch plans, the regulatory setback introduces new challenges for Dexcom’s continuous glucose monitors at a time when competition from Abbott and Medtronic is intensifying.
